
Countries
Headquarters
Naarden, NL
Investment Focus
Biotech, Life Sciences, Pharmaceuticals, Therapeutics, Oncology, Immunology, Nephrology, Chronic Diseases, Cell Therapy, Synthetic Lethality in Cancer
BioGeneration Ventures (BGV) is a venture capital firm specializing in seed investments in innovative early-stage European life sciences companies. BGV typically acts as the lead investor, focusing on biotech companies developing disruptive solutions for high unmet medical needs. BGV is the early-stage strategy of the Forbion-BGV platform of funds, which also includes Forbion Ventures and Forbion Growth. The firm supports biotech companies throughout all stages of development, from company formation (Build, Seed, Series A) through company building (Build, Enable, Series A-B) and company expansion (Crossovers, VIPE/PIPE, Series B/C). They look for opportunities to translate rough scientific ideas into therapeutic products, emphasizing patient impact and attracting additional investment.
Track your relationship with BioGeneration Ventures and manage next steps in your fundraising CRM.
Use GRID's AI-powered VC matcher to find investors that are the best fit for your startup based on sector, stage, geography, and more.
Get AI-Powered Matching Back to DirectoryOlga Ziessen
Unknown
Alexander Vos
Venture Partner
Arnoud Dijkstra
Venture Partner
Arnoud Dijkstra, PhD
Venture Partner
Daniela Couto
General Partner
Daniela Couto, PhD
General Partner
Diede Brunen, PhD
Principal
Edward van Wezel
Managing Partner
Elena Ritsou
Venture Partner
Elisa Camorani, MSc
Senior Associate ESG and Impact
Joern-Peter Halle, PhD
Venture Partner
Keno Gutierrez, PhD
General Partner
Oskar Slotboom
Managing Partner
Rianne Ellenbroek, PhD
Principal
Rob de Ree
Venture Partner
Robbert van de Griendt
Head of Investment Relations
Wouter Verhoeven
Venture Partner
Rachelle Young
Investor Relations Director
John J.P. Kastelein
Senior Advisor
John J.P. Kastelein, MD PhD FESC
Senior Advisor